GeneOne Life Science, Inc. (KRX:011000)

South Korea · Delayed Price · Currency is KRW

2,670.00

-215.00 (-7.45%)

Sep 6, 2026, 3:08 AM KST

Market Cap	48.42B -78.0%
Revenue (ttm)	12.37B -64.4%
Net Income	-48.94B
EPS	-2,698.45
Shares Out	18.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	498,486
Open	2,995.00
Previous Close	2,885.00
Day's Range	2,600.00 - 2,995.00
52-Week Range	2,600.00 - 13,425.00
Beta	0.72
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1976

Employees 41

Stock Exchange Korea Stock Exchange

Ticker Symbol 011000

Full Company Profile

Financial Performance

In 2025, GeneOne Life Science's revenue was 23.04 billion, a decrease of -35.49% compared to the previous year's 35.72 billion. Losses were -51.85 billion, 6.83% more than in 2024.

Financial Statements